Citations

Mayo Clinic

Showing 10 of 108551 citations.

Redirecting pedicle screws: a revision spinal fusion strategy using three‐dimensional image guidance
Nottmeier, Eric W. , Rahmathulla, Gazanfar , Fenton, Douglas S., Pirris, Stephen M. , Yoon, Jang W.

The International Journal of Medical Robotics and Computer Assisted Surgery | January 12, 2016 | Volume: 12 | Issue: 4 | Pages: 758-764

10.1002/rcs.1721 | PMID 26756720 Get It

AbstractBackgroundPedicle screws are a preferred method for spinal fixation because of their three‐column support and rigid posterior stabilization. The purpose of this study was to evaluate the outcome of patients requiring pedicle screw redirection, and to describe a technique using cone‐beam computed tomography (cbCT).MethodsA retrospective review of 30 patients undergoing revision spinal fusion with redirection of pedicle screws was performed. Fifty pedicle screws were redirected in these patients using cbCT‐based 3D image guidance. They were graded pre‐ and post‐operatively using an established grading system.ResultsNo complications occurred in this study as a result of redirection. No pedicle breach was noted in all of the redirected pedicle screws.ConclusionRedirection of misplaced pedicle screws using cbCT‐based 3D image guidance seems to be safe and accurate in our experience. Further studies are needed to establish its safety, accuracy, fusion rate, and clinical outcome compared with other methods. Copyright © 2016 John Wiley & Sons, Ltd.
Benzalkonium Chloride: A Known Irritant and Novel Allergen
Wentworth, Ashley B., Yiannias, James A. , Davis, Mark D.P. , Killian, Jill M.

Dermatitis® | January 12, 2016 | Volume: 27 | Issue: 1 | Pages: 14-20

10.1097/der.0000000000000160 | PMID 26756511 Get It

Background Benzalkonium chloride (BAK), a detergent and preservative found in health care and household products, is an established irritant, yet BAK is seldom considered to cause allergic contact dermatitis. We have, however, observed positive patch test reactions more often than is typically reported. From 2001 through 2005 and 2006 through 2010, BAK was among the top 10 most frequent allergens in our standard series. Objective The aim of this study was to review the Mayo Clinic experience from 2000 to 2012 with patch testing to BAK. Methods An electronic patch test database was used to acquire results of patients who underwent patch testing for BAK 0.1% aqueous after it was introduced to the standard series in 2000 until 2012. Previous reports (1998–2000, 2001–2005, 2006–2010) from our institution were also reviewed. Conclusions Our study showed BAK to be an allergen of increasing importance. From 1998 through 2000, 2001 through 2005, and 2006 through 2010, the rate of allergic patch test results to BAK increased. More than half of the reactions in each period studied were graded as macular erythema, with at least one third of all reactions deemed to be relevant. Irritancy rates were consistently low.
Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907
Lichtman, Stuart M. , Cirrincione, Constance, Hurria, Arti , Jatoi, Aminah , Theodoulou, Maria, Wolff, Antonio C. , Morganstern, Daniel, Magrinat, Gustav , Cohen, Harvey Jay, Muss, Hyman B. , Cirrincione, Constance T, Gralow, Julie, Morganstern, Daniel E, Gralow, Julie R. , Wolff, Antonio C , Lichtman, Stuart M

Journal of Clinical Oncology | January 12, 2016 | Volume: 34 | Issue: 7 | Pages: 699-705

10.1200/jco.2015.62.6341 | PMID 26755510 Get It

Purpose CALGB 49907 showed the superiority of standard therapy, which included either cyclophosphamide/doxorubicin (AC) or cyclophosphamide/methotrexate/fluorouracil over single-agent capecitabine in the treatment of patients age ≥ 65 with early-stage breast cancer. The treatment allowed dosing adjustments of methotrexate and capecitabine for pretreatment renal function. The purpose of the current analysis was to assess the relationship between pretreatment renal function and five end points: toxicity, dose modification, therapy completion, relapse-free survival, and overall survival. Methods Pretreatment renal function was defined as creatinine clearance (CrCl) using the Cockcroft-Gault equation. Multivariable logistic and proportional hazards regression were used to model separately for each regimen the relationship between CrCl and the first three binary end points and the last two time-to-event end points, respectively, after adjusting for variables of prognostic importance. Results Six hundred nineteen assessable patients were analyzed. The incidence of stage III (moderate) or stage IV (severe) renal dysfunction was 72%, 64%, and 75% for treatment with cyclophosphamide/methotrexate/fluorouracil, AC, and capecitabine, respectively. There was no relationship for any regimen between pretreatment renal function and the five end points. For AC, as CrCl increased, the odds of nonhematologic toxicity decreased (P = .008), whereas for capecitabine, as CrCl increased, the odds of experiencing toxicity of any type also increased (P = .035). Patients with renal insufficiency who received dose modifications were not at increased risk for complications compared with those who did not have renal insufficiency and received a full dose. Conclusion Excluding from clinical trials patients with renal insufficiency but good performance status on the basis of concern of excessive hematologic toxicity or poor outcomes may not be justified with appropriate dosing modifications. Results should be considered in the design of clinical trials for older patients.
Anatomy of the Adductor Magnus Origin
Obey, Mitchel R. , Spinner, Robert J. , Collins, Mark S., Krych, Aaron J. , Broski, Stephen M. , Krych, Aaron J

Orthopaedic Journal of Sports Medicine | January 11, 2016 | Volume: 4 | Issue: 1 | Pages: No page available

10.1177/2325967115625055 | PMID 26798764 Get It

Background: The adductor magnus (AM) has historically been a potential source of confusion in patients with suspected proximal hamstring avulsion injuries. Purpose: To investigate the anatomic characteristics of the AM, including its osseous origin, anatomic dimensions, and relationship to the proximal hamstring tendons. Study Design: Descriptive laboratory study. Methods: Dissection of the AM origin was performed in 11 (8 cadavers) fresh-frozen hip-to-foot cadaveric hemipelvis specimens. The gross anatomy and architecture of the proximal hamstring and AM tendons were studied. After dissecting the hamstring tendons away from their origin, the dimension, shape, and orientation of the tendon footprints on the ischial tuberosity were determined. Results: The AM was identified in all cadaveric specimens. The mean tendon thickness (anterior to posterior [AP]) was 5.7 ± 2.9 mm. The mean tendon width (medial to lateral [ML]) was 7.1 ± 2.2 mm. The mean tendon length was 13.1 ± 8.7 cm. The mean footprint height (AP dimension) was 12.1 ± 2.9 mm, and mean footprint width (ML dimension) was 17.3 ± 7.1 mm. The mean distance between the AM footprint and the most medial aspect of the conjoint tendon footprint was 8.5 ± 4.2 mm. Tendon measurements demonstrated a considerable degree of both intra- and interspecimen variability. Conclusion: The AM tendon is consistently present just medial to the conjoint tendon at the ischial tuberosity, representing the lateral-most portion of the AM muscle. This study found wide variation in the dimensional characteristics of the AM tendon between specimens. Its shape and location can mimic the appearance of an intact hamstring (conjoint or semimembranosus) tendon intraoperatively or on diagnostic imaging, potentially misleading surgeons and radiologists. Therefore, detailed knowledge of the AM tendon anatomy, footprint anatomy, and its relationship to the hamstring muscle complex is paramount when planning surgical approach and technique. Clinical Relevance: The reported data may aid surgeons in more accurate recognition, diagnosis, and repair of proximal hamstring avulsion injuries.
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups
Luskin, Marlise R. , Lee, Ju-Whei, Fernández, Hugo F. , Bennett, John M. , Ketterling, Rhett P. , Levine, Ross L. , Litzow, Mark R. , Paietta, Elisabeth , Patel, Jay P., Racevskis, Janis, Rowe, Jacob M. , Tallman, Martin S. , Sun, Zhuoxin , Luger, Selina M. , Luskin, Marlise R , Lee, Ju‐Whei , Abdel‐Wahab, Omar , Lazarus, Hillard M. , Ketterling, Rhett P

Blood | January 11, 2016 | Volume: 127 | Issue: 12 | Pages: 1551-1558

10.1182/blood-2015-07-657403 | PMID 26755712 Get It

Key Points High-dose daunorubicin benefits AML patients with favorable and intermediate cytogenetics and with FLT3-ITD, NPM1, and DNMT3A mutations. High-dose daunorubicin is required for the favorable impact of the NPM1 mutation in AML.
Exudative Macular Detachment After Viral Illness With Rash
Maxfield, Steven D., Barkmeier, Andrew J.

JAMA Ophthalmology | January 11, 2016 | Volume: 134 | Issue: 3 | Pages: 335

10.1001/jamaophthalmol.2015.3585 | PMID 26747787 Get It

The Current Approach to Diagnosis and Management of Left Ventricular Noncompaction Cardiomyopathy: Review of the Literature
Bennett, Courtney , Freudenberger, Ronald S., Bennett, Courtney E

Cardiology Research and Practice | January 11, 2016 | Volume: 2016 | Issue: No issue available | Pages: 1-7

10.1155/2016/5172308 | PMID 26881173 Get It

Isolated left ventricular noncompaction (LVNC) is a genetic cardiomyopathy characterized by prominent ventricular trabeculations and deep intertrabecular recesses, or sinusoids, in communication with the left ventricular cavity. The low prevalence of patients with this cardiomyopathy presents a unique challenge for large, prospective trials to assess its pathogenesis, management, and outcomes. In this paper we review the embryology and genetics of LVNC, the diagnostic approach, and propose a management approach based on the current literature available.
Robert Williams Wood: pioneer of invisible light
Sharma, Shruti , Sharma, Amit

Photodermatology, Photoimmunology & Photomedicine | January 11, 2016 | Volume: 32 | Issue: 2 | Pages: 60-65

10.1111/phpp.12235 | PMID 26752503 Get It

SummaryThe Wood's lamp aids in the diagnosis of multiple infectious, inflammatory and neoplastic dermatologic conditions. Although the Wood's lamp has many applications, which have improved both the diagnosis and management of disease, the man credited for its invention is relatively unknown in medicine. Robert Williams Wood, a prominent physicist of the early 20th century, is credited for the invention of the Wood's lamp. Wood was the father of infrared and ultraviolet photography and made significant contributions to other areas in optics and spectroscopy. Wood's work encompassed the formative years of American Physics; he published over 200 original papers over his lifetime. A few years after the invention of the Wood's lamp for ultraviolet photography, physicians in Europe adopted the Wood's lamp for dermatologic applications. Wood's lamp remains popular in clinics globally, given its ease of use and ability to improve diagnostic precision.